China Shenghuo Pharmaceutical Holdings, Inc. will restate its financial reports from the past twelve months, saying that the company has discovered errors in sales commission advances and trade receivables. The Audit Committee and an independent counsel will review Shenghuo’s internal controls and the personnel who are involved. The company did not hint at the magnitude of the restatement, though it does expect to complete the review and present restated results within two months. More details...

Stock Symbol: (AMEX: KUN)